Rice Hall James & Associates LLC Has $16.90 Million Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Rice Hall James & Associates LLC decreased its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 2.4% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 515,889 shares of the specialty pharmaceutical company's stock after selling 12,456 shares during the period. Supernus Pharmaceuticals makes up 1.0% of Rice Hall James & Associates LLC's portfolio, making the stock its 29th biggest holding. Rice Hall James & Associates LLC owned 0.92% of Supernus Pharmaceuticals worth $16,895,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the business. Principal Financial Group Inc. boosted its holdings in Supernus Pharmaceuticals by 3.2% during the first quarter. Principal Financial Group Inc. now owns 306,322 shares of the specialty pharmaceutical company's stock worth $10,032,000 after buying an additional 9,590 shares in the last quarter. Meritage Portfolio Management lifted its position in shares of Supernus Pharmaceuticals by 22.0% during the 1st quarter. Meritage Portfolio Management now owns 58,803 shares of the specialty pharmaceutical company's stock valued at $1,926,000 after acquiring an additional 10,622 shares during the last quarter. Robeco Institutional Asset Management B.V. bought a new stake in shares of Supernus Pharmaceuticals during the 1st quarter worth $267,000. QRG Capital Management Inc. grew its holdings in shares of Supernus Pharmaceuticals by 5.5% in the 1st quarter. QRG Capital Management Inc. now owns 17,583 shares of the specialty pharmaceutical company's stock worth $576,000 after acquiring an additional 913 shares during the last quarter. Finally, Exchange Traded Concepts LLC raised its position in shares of Supernus Pharmaceuticals by 12.5% during the first quarter. Exchange Traded Concepts LLC now owns 24,881 shares of the specialty pharmaceutical company's stock worth $815,000 after purchasing an additional 2,762 shares during the period.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen raised Supernus Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Saturday.

Supernus Pharmaceuticals Price Performance

Supernus Pharmaceuticals stock traded up $0.84 during midday trading on Monday, reaching $33.96. The stock had a trading volume of 594,612 shares, compared to its average volume of 567,557. The firm's fifty day simple moving average is $32.26 and its two-hundred day simple moving average is $33.73. Supernus Pharmaceuticals, Inc. has a twelve month low of $27.05 and a twelve month high of $40.28. The firm has a market cap of $1.90 billion, a price-to-earnings ratio of 30.59 and a beta of 0.70.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.